معرفی
Veronika Wingstedt serves as a Researcher within the Department of Medicinal Chemistry at Uppsala University, where she contributes to the Platform for Preclinical PET-MRI. Her technical expertise focuses on engineering advanced imaging protocols for biomedical research, specifically in the development and application of multimodal imaging techniques including PET, SPECT, and CT for preclinical disease modeling and drug evaluation.
Her core research spans Nuclear Medicine, Molecular Imaging, and Radiopharmaceutical Chemistry, with specialized contributions in radiotracer synthesis (particularly C-11 and Ga-68 compounds), bone regeneration imaging, cancer theranostics, and endocrine disorder diagnostics. She integrates radiochemistry with molecular biology to develop imaging probes for bone morphogenetic protein tracking, insulinoma detection, and HER2-targeted prostate cancer therapy, emphasizing translational applications from preclinical validation to clinical feasibility studies.
Analysis of her publication timeline (2012-2018) reveals consistent innovation in multimodal imaging probe development, with increasing focus on theranostic applications. Her work demonstrates methodological rigor in dosimetry calculations, radiolabeling optimization, and validation of imaging protocols across diverse disease models. Key thematic threads include the engineering of tri-modal visualization systems, precision targeting of molecular pathways in cancer, and quantitative assessment of physiological processes like cerebral blood flow during surgical interventions.
No scientific awards, fellowships, or medals are documented in the provided materials. The available information does not specify graduate student advising relationships or external grant funding, though her extensive collaborative publication record indicates active participation in multidisciplinary research teams.
As a core technical contributor to Uppsala University's Platform for Preclinical PET-MRI, Wingstedt supports biomedical research through state-of-the-art imaging infrastructure. This platform enables high-resolution quantitative studies across oncology, endocrinology, and bone disease research, with her engineering expertise directly enhancing capabilities in radiotracer development, multimodal imaging protocol design, and preclinical model validation.
